相关实验视频
Updated: Mar 3, 2026

06:50
Extraction and Analysis of Taiwanese Green Propolis
Published on: January 7, 2019
9.3K
子补充剂和代谢综合征组件在成年人处于危险之中:随机对照试验的系统审查和元分析
Safia Obaidur Rab1, Mudher Kadhem2,3,4, Malathi H5
1Department of Clinical Laboratory Sciences, College of Applied Medical Sciences King Khalid University Abha Saudi Arabia.
Health science reports
|March 2, 2026
概括
прополис补充剂显著降低了成年人患代谢综合征风险的禁食血糖和甘油三水平. 然而,它没有影响其他代谢综合征成分,因此需要进一步研究.
科学领域:
- 营养科学 营养科学
- 代谢健康 代谢健康
- 自然产品研究 自然产品研究
背景情况:
- 蜂是一种来自蜜蜂的树脂,具有已知的抗氧化和抗炎性质.
- 之前对 прополис和代谢综合征 (MetS) 成分的研究产生了不一致的结果.
- 需要进行全面的元分析,以澄清 прополис对风险成年人MetS的影响.
研究的目的:
- 系统地评估 прополис补充剂对代谢综合征成分的影响.
- 综合和MetS指标随机对照试验 (RCT) 的证据.
- 为了更清楚地了解 прополис在管理 MetS 风险因素方面的潜在作用.
主要方法:
- 在主要的科学数据库中进行了系统的文献搜索,直到2025年7月.
- 包含的研究是随机对照试验 (RCT),调查 MetS 风险的成年人补充剂.
- 用随机效应模型分析数据,以计算加权平均差异 (WMD).
主要成果:
- 分析包括20个RCT,共1091名参与者.
- прополис显著降低了空腹血糖 (FBS) (WMD: -7.93 mg/dL) 和甘油三 (TG) 水平 (WMD: -12.32 mg/dL).
- 没有观察到对腰围,高密度胆固醇 (HDL) 胆固醇,静缩或静缩血压的显著影响.
结论:
- 蜂补充剂在患有MetS风险因素的个体中显示出对血糖和甘油三控制的潜在益处.
- 目前的证据表明, прополис不会显著影响其他MetS成分,如血压或高密度胆固醇.
- 建议进一步进行高质量的RCT,随访时间更长,以确认这些发现并探索机制.
相关概念视频
Atherosclerosis III: Management
523
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
523
Oral Hypoglycemic Agents: Biguanides and Glitazones
739
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
739

